GeoVax Labs, Inc. (Nasdaq: GOVX) today commented on the U.S. government's recent procurement of additional ACAM2000® smallpox vaccine from Emergent BioSolutions, noting that the award reinforces the strategic importance of maintaining robust orthopoxvirus preparedness capabilities. The procurement reflects ongoing commitment to the Strategic National Stockpile and sustaining multiple medical countermeasures against smallpox and mpox threats.
"Government procurement decisions are driven by long-term national preparedness objectives rather than short-term outbreak cycles," said David Dodd, Chairman and CEO of GeoVax. "Continued federal investment in orthopox preparedness reinforces the importance of resilient manufacturing capacity, diversified vaccine supply, and regulatory readiness. We believe this environment strongly supports the accelerated development of GEO-MVA through its expedited regulatory pathway and the expansion of U.S.-based MVA vaccine manufacturing."
The announcement comes amid an evolving global health security landscape marked by recurring mpox outbreaks, emergence of high-consequence infectious diseases, and renewed emphasis on domestic manufacturing of critical medical countermeasures. These trends reinforce the importance of maintaining a resilient and diversified biodefense infrastructure capable of responding to naturally occurring outbreaks and potential biological threats.
GeoVax believes these long-term policy priorities align with the objectives of its GEO-MVA program. GEO-MVA is the company's Modified Vaccinia Ankara (MVA)-based vaccine candidate for mpox and smallpox, designed to provide a U.S.-manufactured, non-replicating MVA vaccine for public health and biodefense preparedness.
Following positive scientific advice from the European Medicines Agency (EMA), GeoVax is pursuing an expedited clinical development strategy using immunobridging to an approved MVA vaccine, allowing advancement directly into a single, registrational Phase 3 study without traditional Phase 1 or 2 efficacy studies. The pivotal Phase 3 study is scheduled to initiate in the fourth quarter of 2026, with data readout of the immunobridging portion anticipated by mid-2027.
For more information about GeoVax and its programs, visit www.geovax.com.
